The Drug Enforcement Administration (DEA), the federal agency that oversees drug distribution of Controlled Substances, is responsible for setting quotas and controlling the amount of drug that may be legally produced.

In this case, there apparently was a shortfall of ADHD medications in 2022 because there was an enormous increase in the diagnosis of ADHD during the Covid Pandemic and the pharmaceutical manufacturers failed to produce the full amount of approved drug, causing a one billion dose shortfall for 2023 and the great catch-up ensued.

One billion doses. Geesh! A billion here and a billion there and pretty soon we're talking about real drugging!

Nevertheless, in order to get up to speed (no pun intended), it was requested of the DEA by the Food and Drug Administration, (FDA) to increase the aggregate production quota (APQ) for lisdexamfetamine and a corresponding increase of D-amphetamine "because this substance is used by some manufacturers as part of the synthesis pathway to manufacture lisdexamfetamine."

This request for drug increase was posted in the Federal Register in September of this year for review, public consumption, and response. But in this case, the public was not allowed to comment on the requested drug increase because the DEA would not meet the Congressional mandated 30-day period.

In fact, the public regularly is shut out of the public comment opportunities that are mandated and required by law.

AbleChild is routinely prevented from participating in the State Connecticut's Behavioral Health Partnership Oversight Council, even to the point of having the mic cut mid-sentence. It appears that those overseeing the ADHD and other psychiatric drugs don't like to hear from those concerned about the dangers associated with the "treatments."

However, despite no public input, the DEA explained the need for increased stimulants this way, "manufacturers of drugs that are life-supporting, life-sustaining, or intended for the treatment or prevention of debilitating diseases or conditions must notify FDA of any permanent discontinuation or interruption in manufacturing likely to result in a meaningful disruption on the drug's supply in the United States."